-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
CureVac (NASDAQ:CVAC) Hits New 12-Month Low at $9.35
CureVac (NASDAQ:CVAC) Hits New 12-Month Low at $9.35
CureVac (NASDAQ:CVAC – Get Rating) hit a new 52-week low during trading on Monday . The stock traded as low as $9.35 and last traded at $9.47, with a volume of 107 shares traded. The stock had previously closed at $9.57.
Analyst Ratings Changes
Separately, JMP Securities restated a "buy" rating and set a $37.00 target price on shares of CureVac in a research report on Thursday, June 9th.
Get CureVac alerts:CureVac Price Performance
The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.39 and a current ratio of 3.45. The firm has a 50 day moving average price of $12.02 and a 200-day moving average price of $15.09.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in CVAC. Capital Fund Management S.A. raised its stake in shares of CureVac by 131.9% during the 1st quarter. Capital Fund Management S.A. now owns 233,371 shares of the company's stock worth $4,576,000 after buying an additional 132,757 shares during the last quarter. Swiss National Bank acquired a new position in CureVac in the 2nd quarter valued at about $1,786,000. BlackRock Inc. raised its stake in CureVac by 6.2% in the 1st quarter. BlackRock Inc. now owns 1,915,548 shares of the company's stock valued at $37,564,000 after purchasing an additional 111,590 shares during the last quarter. Citigroup Inc. raised its stake in CureVac by 120.2% in the 1st quarter. Citigroup Inc. now owns 16,469 shares of the company's stock valued at $323,000 after purchasing an additional 98,177 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in CureVac by 156.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 158,520 shares of the company's stock valued at $2,157,000 after purchasing an additional 96,801 shares during the last quarter.CureVac Company Profile
(Get Rating)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
Featured Stories
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
CureVac (NASDAQ:CVAC – Get Rating) hit a new 52-week low during trading on Monday . The stock traded as low as $9.35 and last traded at $9.47, with a volume of 107 shares traded. The stock had previously closed at $9.57.
納斯達克(CureVac：CVAC-GET評級)在週一的交易中創下52周新低。該股最低交易價格為9.35美元，最新報9.47美元，成交量為107股。該股此前收盤價為9.57美元。
Analyst Ratings Changes
分析師評級發生變化
Separately, JMP Securities restated a "buy" rating and set a $37.00 target price on shares of CureVac in a research report on Thursday, June 9th.
另外，JMP證券在6月9日(星期四)的一份研究報告中重申了“買入”評級，併為CureVac的股票設定了37.00美元的目標價。
CureVac Price Performance
CureVac性價比
The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.39 and a current ratio of 3.45. The firm has a 50 day moving average price of $12.02 and a 200-day moving average price of $15.09.
該公司的負債權益比率為0.06，速動比率為3.39，流動比率為3.45。該公司的50日移動均線價格為12.02美元，200日移動均線價格為15.09美元。
Institutional Inflows and Outflows
機構資金流入和流出
CureVac Company Profile
CureVac公司簡介
(Get Rating)
(獲取評級)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
CureVac N.V.是一家臨牀階段的生物製藥公司，專注於開發基於信使核糖核酸(MRNA)的各種變革性藥物。它正在開發預防疫苗，如處於SARS-CoV-2第一階段臨牀試驗的mRNA候選疫苗CV2CoV；已完成狂犬病病毒糖蛋白第一階段臨牀試驗的基於mRNA的預防性疫苗CV7202；處於流感第一階段臨牀試驗的CVSQIV，以及拉沙熱、黃熱病、呼吸道合胞病毒、輪狀病毒、瘧疾和通用流感疫苗。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- 免費獲取StockNews.com關於CureVac(CVAC)的研究報告
- 聯邦快遞剛剛提供了一個買入機會嗎？
- 自動區重新進入拉力賽模式，新高在望
- Upwork股價跌入便宜貨領域
- 克羅格百貨是你的一站式消費者史泰博股票
- Adobe為投資者完善Facebook工廠的藝術
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
接受CureVac Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對CureVac和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧